source
- State incentives can shape site decisions for commercial-stage life sciences firmsThe article advises commercial-stage life-science companies to consider state and local incentives early in expansion planning to improve site selection and preserve capital. Incentives most relev…
- Zura Bio halts hidradenitis suppurativa program after tibulizumab fails phase 2 trialZura Bio announced it is ending development of tibulizumab for hidradenitis suppurativa after the drug did not meet the primary endpoint in a phase 2 study. The trial, called Tibushield, compared t…